Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT2385 in recurrent glioblastoma
NCT03216499Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2017
- Primary completion
- Aug 2019
- Countries
- 1
01
Overview
A Phase 2 trial of PT-2385 in glioblastoma (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Sep 2017; status: completed.
02
Drugs
PT-2385
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03216499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216499.